Last year, Enzon Pharmaceuticals terminated its co-development agreement with Inex after the FDA issued a "non-approvable" letter for Marqibo, saying Phase III trials were necessary.
FORBES: Magazine Article
Inex will also receive a royalty.
应用推荐
模块上移
模块下移
不移动